- Oops!Something went wrong.Please try again later.
Shares of Haemonetics (NYSE:HAE) fell 0.1% in pre-market trading after the company reported Q2 results.
Earnings per share fell 28.74% over the past year to $0.62, which beat the estimate of $0.51.
Revenue of $209,486,000 decreased by 17.06% year over year, which beat the estimate of $207,650,000.
Earnings guidance hasn't been issued by the company for now.
Haemonetics hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: Nov 04, 2020
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/ge7vnpw8
52-week high: $130.75
52-week low: $63.41
Price action over last quarter: Up 34.28%
Haemonetics Corp sells products used to process, handle, and analyze blood. The firm sells products in four categories: Plasma, Hemostasis Management, Blood Center and Cell Processing. The Plasma business includes plasma collection devices and disposables. Hemostasis Management includes devices and methodologies for measuring coagulation characteristics of blood, Blood Center includes blood collection and processing devices and disposables for red cells and Cell Processing include surgical blood salvage systems, specialized blood cell processing systems, disposables and blood transfusion management software.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.